showed a trendp =0.06
Overall mPFS was not reached; in patients with dnMBC, mPFS was not reached and multivariate analysis showed a trend towards a longer PFS (HR 0.47; p =0.06) when compared with patients with early rMBC (<12 months) and/or recurring during adjuvant therapy. 79 In summary, results of both clinical trials and real-world studies appear to confirm that patients with dnMBC respond better to systemic treatments; whether this improved benefit derives from a lower likelihood of acquired resistance or to intrinsic genetic and biological peculiarities, for example, reduced heterogeneity, needs still to be clarified.